SLFN11 and small cell lung carcinoma: PARPs mediate DNA damage responses and small cell lung cancer (SCLC) PDXs lacking SLFN11 expression were found to be resistant to the PARPi talazoparib as compared to PDXs that expressed high levels of SLFN11.